Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · IEX Real-Time Price · USD
1.17
0.00 (-0.43%)
Dec 7, 2022 3:59 PM EST - Market closed
-0.43%
Market Cap 59.28M
Revenue (ttm) 47.57M
Net Income (ttm) -17.85M
Shares Out 49.50M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Ex-Dividend Date n/a
Volume 66,303
Open 1.15
Previous Close 1.17
Day's Range 1.15 - 1.18
52-Week Range 0.7 - 2
Beta 1.61
Analysts Buy
Price Target 11.22 (+863.1%)
Earnings Date Nov 14, 2022

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a ... [Read more]

Industry Biotechnology
IPO Date May 15, 1998
CEO Dror Bashan
Employees 202
Stock Exchange NYSEAMERICAN
Ticker Symbol PLX
Full Company Profile

Financial Performance

In 2021, PLX's revenue was $38.35 million, a decrease of -39.03% compared to the previous year's $62.90 million. Losses were -$27.58 million, 322.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PLX stock is "Buy." The 12-month stock price forecast is 11.22, which is an increase of 863.09% from the latest price.

Price Target
$11.22
(863.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a R...

CARMIEL, Israel and BOSTON , Dec. 5, 2022 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commerciali...

2 days ago - PRNewsWire

Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Nov. 14, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical co...

3 weeks ago - PRNewsWire

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U....

CARMIEL, Israel and BOSTON , Nov. 14, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerc...

3 weeks ago - PRNewsWire

Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company f...

1 month ago - PRNewsWire

Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference

CARMIEL, Israel , Sept. 12, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization o...

2 months ago - PRNewsWire

Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARMIEL, Israel , Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

3 months ago - PRNewsWire

Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 15, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical co...

3 months ago - PRNewsWire

Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15,...

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 8, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company f...

3 months ago - PRNewsWire

Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

CARMIEL, Israel , June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi...

5 months ago - PRNewsWire

Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease

CARMIEL, Israel , May 26, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

6 months ago - PRNewsWire

Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 16, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical com...

6 months ago - PRNewsWire

Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , May 9, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focu...

6 months ago - PRNewsWire

Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsidase alfa...

8 months ago - Benzinga

Why Protalix BioTherapeutics Stock Is Soaring

Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited dise...

8 months ago - Benzinga

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE...

CARMIEL, Israel and BOSTON, April 4, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerci...

8 months ago - PRNewsWire

Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results

CARMIEL, Israel, March 31, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

8 months ago - PRNewsWire

Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 24, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:  PLX), a biopharmaceutical company...

8 months ago - PRNewsWire

Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have announced final results from the BRIGHT Phase 3 trial of pegunigalsidase alfa (PRX‑102...

8 months ago - Benzinga

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Tria...

CARMIEL, Israel and BOSTON , March 18, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commer...

8 months ago - PRNewsWire

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Applica...

CARMIEL, Israel and BOSTON, Feb. 24, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization...

9 months ago - PRNewsWire

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022

CARMIEL, Israel, Feb. 3, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

10 months ago - PRNewsWire

Protalix BioTherapeutics Issues 2021 Letter to Stockholders

CARMIEL, Israel, Dec. 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

11 months ago - PRNewsWire

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

CARMIEL, Israel, Nov. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

1 year ago - PRNewsWire

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update ...

CARMIEL, Israel, Nov. 8, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

1 year ago - PRNewsWire

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE C...

CARMIEL, Israel and BOSTON, Oct. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerci...

1 year ago - PRNewsWire